What is Biomesense?
Biomesense operates at the intersection of biotechnology and data science, providing a sophisticated platform for the continuous tracking and analysis of gut microbiome data. Through proprietary technologies such as GutLab and MetaBiome, the company offers high-fidelity insights that are essential for clinical research, biomarker discovery, and the development of next-generation therapeutic products. By serving a diverse clientele of leading scientists and enterprise-level research organizations, Biomesense has established itself as a critical infrastructure provider in the global health landscape. The company's focus on generating comprehensive, longitudinal microbiome datasets enables its partners to unlock new potential in patient outcomes and precision diagnostics, effectively bridging the gap between raw biological data and actionable clinical intelligence.
How much funding has Biomesense raised?
Biomesense has raised a total of $3M across 1 funding round:
Other Financing Round
$3M
Other Financing Round (2023): $3M with participation from Bluestein Ventures, SOSV, and Harvest Ridge Capital
Key Investors in Biomesense
Bluestein Ventures
A venture capital firm focused on early-stage, game-changing ventures within the food industry, providing both capital and strategic network support.
SOSV
A multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
Harvest Ridge Capital
An investment firm focused on identifying and supporting high-growth potential companies through strategic capital allocation.
What's next for Biomesense?
With this major enterprise-level funding, Biomesense is poised to scale its operational capacity and expand its footprint within the clinical research sector. The strategic allocation of capital will likely prioritize the enhancement of its AI-driven analytical engine and the broadening of its MetaBiome platform capabilities. As the company transitions into its next phase of growth, the focus will remain on deepening partnerships with global pharmaceutical and biotech entities to standardize microbiome data collection. By maintaining its commitment to rigorous scientific validation and technological innovation, Biomesense is set to solidify its market leadership, ultimately transforming how the industry approaches personalized medicine and chronic disease management on a global scale.
See full Biomesense company page
